Post-COVID syndrome, inflammation, and diabetes

The CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO)

Research output: Contribution to journalReview articlepeer-review

Abstract

The raging COVID-19 pandemic is in its third year of global impact. The SARS CoV 2 virus has a high rate of spread, protean manifestations, and a high morbidity and mortality in individuals with predisposing risk factors. The pathophysiologic mechanisms involve a heightened systemic inflammatory state, cardiometabolic derangements, and varying degrees of glucose intolerance. The latter can be evident as significant hyperglycemia leading to new-onset diabetes or worsening of preexisting disease. Unfortunately, the clinical course beyond the acute phase of the illness may persist in the form of a variety of symptoms that together form the so-called “Long COVID” or “Post-COVID Syndrome”. It is thought that a chronic, low-grade inflammatory and immunologic state persists during this phase, which may last for weeks or months. Although numerous insights have been gained into COVID-related hyperglycemia and diabetes, its prediction, course, and management remain to be fully elucidated.

Original languageEnglish
Article number108336
JournalJournal of Diabetes and its Complications
Volume36
Issue number11
DOIs
Publication statusPublished - Nov 2022

Keywords

  • COVID-19
  • Long COVID
  • New-onset diabetes
  • Newly diagnosed diabetes
  • Post-COVID syndrome
  • SARS CoV-2
  • Syndemia
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this